)
Visual
test
Medicenna Therapeutics
Medicenna Therapeutics (MDNA) investor relations material
Medicenna Therapeutics KOL Event summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.KOL Event summary10 Dec, 2025
Introduction and agenda
The event presented updated clinical data from the ABILITY-1 Phase 1/2 study of MDNA11 in advanced solid tumors, including monotherapy and combination with checkpoint inhibitors, and was discussed at ESMO Immuno-Oncology Congress 2025.
The agenda covered trial design, patient characteristics, safety, efficacy, mechanistic insights, future development plans, principal investigator perspectives, KOL commentary, and Q&A.
Webinar hosted with management, principal investigator, and key opinion leaders to discuss results and future directions.
KOL background and credentials
Key opinion leaders included Dr. Hussein Tawbi (MD Anderson), Dr. Igor Puzanov (Roswell Park), Dr. Paolo Ascierto (Naples), Dr. Toni Choueiri (Dana-Farber), and principal investigator Dr. André Mansinho, all with expertise in immuno-oncology and drug development.
Market insights and analysis
MDNA11 is a β-enhanced, not-α IL-2 superagonist in clinical development for advanced solid tumors, with both monotherapy and combination arms (with pembrolizumab/KEYTRUDA).
The molecule's unique receptor engagement and clean safety profile differentiate it from other IL-2 variants, addressing unmet needs in refractory and ICI-resistant solid tumors.
MDNA11 shows durable anti-tumor activity in checkpoint-resistant melanoma, MSS endometrial, MSI-H, and TMB-H cancers, exceeding ORR benchmarks in these populations.
External validation from the NEO-CYT trial in high-risk melanoma supports the approach and potential for earlier-stage patients.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebGICRE
Net profit for the nine months surged to ₹6,62,217 lakhs, with a robust solvency ratio of 3.87. - 7 Feb517271
Strong revenue and profit growth, interim dividend, and major investments approved. - 7 Feb514167
Quarterly and nine-month results reflect solid revenue, profit, and compliance with new labour codes. - 7 FebMGL
Strong revenue growth offset by lower margins and profit; interim dividend declared. - 7 FebPGIL
Strong revenue and margin growth, with India set for further expansion and upgraded ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus.
Next Medicenna Therapeutics earnings date
Q3 202610 Feb, 2026
Medicenna Therapeutics
Next Medicenna Therapeutics earnings date
Q3 202610 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Medicenna Therapeutics Corp. is a Canada-based clinical-stage biopharmaceutical company focused on the development of novel immunotherapies for cancer and other diseases. The company’s proprietary platforms are designed to create engineered cytokines, including interleukin-based therapies, aimed at enhancing immune system responses against tumors. The company is headquartered in Toronto, Canada, and its shares are listed on both the NASDAQ and the Toronto Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage